Correlation Between Cogent Biosciences and Inozyme Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cogent Biosciences and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cogent Biosciences and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cogent Biosciences and Inozyme Pharma, you can compare the effects of market volatilities on Cogent Biosciences and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cogent Biosciences with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cogent Biosciences and Inozyme Pharma.

Diversification Opportunities for Cogent Biosciences and Inozyme Pharma

CogentInozymeDiversified AwayCogentInozymeDiversified Away100%
0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Cogent and Inozyme is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Cogent Biosciences and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Cogent Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cogent Biosciences are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Cogent Biosciences i.e., Cogent Biosciences and Inozyme Pharma go up and down completely randomly.

Pair Corralation between Cogent Biosciences and Inozyme Pharma

Given the investment horizon of 90 days Cogent Biosciences is expected to under-perform the Inozyme Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Cogent Biosciences is 1.18 times less risky than Inozyme Pharma. The stock trades about -0.39 of its potential returns per unit of risk. The Inozyme Pharma is currently generating about -0.18 of returns per unit of risk over similar time horizon. If you would invest  142.00  in Inozyme Pharma on November 30, 2024 and sell it today you would lose (22.00) from holding Inozyme Pharma or give up 15.49% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Cogent Biosciences  vs.  Inozyme Pharma

 Performance 
JavaScript chart by amCharts 3.21.15Dec2025Feb -50-40-30-20-10010
JavaScript chart by amCharts 3.21.15COGT INZY
       Timeline  
Cogent Biosciences 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Cogent Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
JavaScript chart by amCharts 3.21.15DecJanFebJanFeb6.577.588.599.51010.5
Inozyme Pharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
JavaScript chart by amCharts 3.21.15DecJanFebJanFeb1.522.533.5

Cogent Biosciences and Inozyme Pharma Volatility Contrast

   Predicted Return Density   
JavaScript chart by amCharts 3.21.15-6.05-4.53-3.01-1.49-0.02311.342.734.125.516.89 0.0100.0150.0200.0250.030
JavaScript chart by amCharts 3.21.15COGT INZY
       Returns  

Pair Trading with Cogent Biosciences and Inozyme Pharma

The main advantage of trading using opposite Cogent Biosciences and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cogent Biosciences position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.
The idea behind Cogent Biosciences and Inozyme Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings